Diego A Díaz García, Medical Oncologist /CEO/Founder at CánCare – High Specialty in Oncology, shared a post on X:
“Biomarkers in renal cell carcinoma: still an unmet need.
ICIs have changed the game in ccRCC, but predictive tools lag behind.
-Why biomarkers successful in other tumor types have fallen short in ccRCC?Emerging predictive and prognostic biomarkers, including gene expression signatures.
Future directions to enable more personalized, biomarker-driven care for patients with kidney cancer.”
Title: Biomarker-informed care for patients with renal cell carcinoma
Journal: Nature Cancer
Authors: Mackenzie B. McKinnon, Brian I. Rini and Scott M. Haake
Read Full Article.
More posts featuring Diego A Díaz García on OncoDaily.
